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Background and PurposezzPrimary involvement of the peripheral nerves in myotonic dys-
trophy type I (MyD1) is controversial. We investigated whether the involvement of peripheral 
nerves is a primary event of MyD1 or secondary to another complication such as diabetes melli-
tus (DM).
MethodszzThe subjects comprised 12 patients with MyD1, 12 with DM and no peripheral nerve 
involvement, and 25 healthy volunteers. We measured multiple excitability indices in the median 
motor axons. The strength-duration time constant was calculated from the duration-charge curve, 
the threshold electrotonus and current-threshold relationships were calculated from the sequential 
subthreshold current, and the recovery cycle was derived from double suprathreshold stimulation.
ResultszzThe depolarizing and hyperpolarizing threshold electrotonus were significantly reduced 
and exhibited increased refractoriness in the MyD1 group compared with the DM and control 
groups. The SDTC, superexcitability, and subexcitability were not significantly altered in the MyD1 
group.
ConclusionszzThe MyD1 group exhibited a depolarized axonal membrane potential. The signifi-
cant differences in peripheral nerve excitability between the MyD1 group and the DM and nor-
mal control groups suggest that peripheral neuropathy is a primary event in MyD1 rather than a 
secondary complication of DM.  J Clin Neurol 2011;7:90-95
Key Wordszz    myotonic dystrophy, neuropathy, threshold tracking, axonal excitability, 
nerve excitability test.
Introduction
Myotonic dystrophy type 1 (MyD1) is an autosomal dominant 
genetic muscle disease caused by the unstable expansion of 
CTG repeats in DMPK, the gene that encodes myotonic dys-
trophy protein kinase on chromosome 19.
1,2 MyD1 has various 
extramuscular manifestations including cataracts, frontal bald-
ness, cardiac conduction defects, and endocrine abnormalities.
2
The primary involvement of the peripheral nerves in MyD1 
is controversial. Several studies have indicated that peripheral 
neuropathy (PN) is an extramuscular manifestation of MyD1,
3-5 
whereas others suggest that certain PNs or peripheral nerve ab-
normalities are a secondary complication caused by diabetes 
mellitus (DM) or drug side effects.
6-8 PN commonly appears 
during the advanced stage of MyD1, when glucose metabo-
lism is significantly impaired;9,10 thus, it is difficult to deter-
mine the role of DM in the development of PN in MyD1. To 
differentiate between these potential causative factors, PN must 
be evaluated during the early stage of MyD1, when glucose me-
tabolism is normal. The presence of overt PN or peripheral 
nerve dysfunction in this stage would indicate primary peri-
pheral nerve involvement in MyD1. The conventional nerve 
conduction study (NCS) that is widely used to diagnose PN has 
a limited ability to detect abnormalities, particularly in the ear-
ly stages of PN,
11,12 and it provides little information concern-
ing the pathophysiology.
The aim of the present study was to determine whether PN is 
a primary manifestation of MyD1 or a secondary complication 
of DM. To accomplish this, we used the automated nerve ex-
citability test (NET) to compare the pattern of nerve excitabi-
lity properties in patients with MyD1 and normal glucose me-
tabolism and NCS findings, with that in patients with DM and 
normal NCS findings.Bae JS et al.
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Methods
Subjects
The subjects were 12 MyD1 patients who visited the Inje Uni-
versity Busan Paik Hospital, Department of Neurology be-
tween April 2009 and May 2010. All of the patients were care-
fully evaluated by an experienced neurologist and showed cli-
nical and electromyographic evidence of myotonia with myo-
pathy. Unstable CTG gene expansions in DMPK were identi-
fied from peripheral blood samples. Patients who had a me-
tabolic or nutritional disease that might cause PN, suspected 
radiculopathy, or entrapment neuropathy were excluded. Tw-
elve patients with DM and normal conventional NCS findings 
were included as early-disease or subclinical PN controls. We 
also analyzed the data of 25 age- and sex-matched healthy 
volunteers as a normal control group. All subjects gave their in-
formed consent to participate, and the study was approved by 
the ethics committee of Inje University College of Medicine.
All patients underwent a routine blood examination, which 
included complete blood count, liver function test, renal func-
tion test, thyroid function test, and lipid battery. If a patient’s 
random glucose concentration was at the upper limit of the 
normal range, an oral glucose tolerance test was performed in 
accordance with the recommendations of the American Dia-
betes Association.
Automated NET
The NET was performed using a computerized program (QT-
RACS with multiple excitability protocol TRONDF; copy-
right, Prof. Hugh Bostock, Institute of Neurology, London, 
UK). Compound muscle action potentials (CMAPs) were re-
corded from the right abductor pollicis brevis muscle after 
stimulation of the median nerve at the wrist (3 cm proximal 
to the wrist crease). Skin temperature was measured near the 
stimulation site and maintained above 31.5ºC. The protocols 
examining stimulus-response curves used durations of 0.2 and 
1.0 ms. The strength-duration time constant (SDTC) was de-
termined using Weiss’s equation to plot threshold charge ag-
ainst stimulation duration. SDTC is given as the (negative) in-
tercept on the duration axis.
13,14
For the following measurements, the current required to 
produce a CMAP that was 40% of the maximum was tracked. 
In the threshold electrotonus (TE) studies, the membrane po-
tential was altered by applying subthreshold DC polarizing 
currents that were 40% of the unconditioned threshold. De-
polarizing and hyperpolarizing currents were used, each last-
ing 100 ms, and their effect on the threshold current for the 
test CMAP was examined. In a further test with subthreshold 
conditioning currents, the test stimulus was delivered at the 
end of a polarizing current pulse lasting 200 ms. The intensity 
of the current pulse was changed systematically from 50% 
depolarizing (TEd) to 100% hyperpolarizing (TEh) in 10% in-
crements. This produced a current-threshold relationship (CTR) 
analogous to a conventional current-voltage relationship. The 
recovery cycle (RC) of axonal excitability after a single supra-
maximal stimulus was measured by delivering the test stimu-
lus at different intervals after the conditioning stimulus. The 
conditioning-test intervals were systematically changed from 
2 to 200 ms.
Statistical analyses
The statistical analyses were carried out using SPSS v10.0 for 
Windows (SPSS, Chicago, IL, USA). The Mann-Whitney U-
test was used to compare continuous variables, and the chi-
squared test was used to compare categorical variables. Spear-
man’s rank correlation was used to determine the correlation 
between two independent continuous variables. The level of 
statistical significance was deemed to be p<0.05. Data are 
presented as mean±SEM values.
Results
Patient characteristics
The characteristics of the patients with MyD1 are summariz-
ed in Table 1. No patient had radiculopathy or precipitating 
factors for PN such as metabolic or nutritional factors, drugs, 
toxins, or trauma. The clinical and laboratory evaluations in-
dicated that no patient had overt DM or impaired glucose to-
lerance. The patients with DM had normal conventional NCS 
results and were rated as N0 according to Dyck’s diabetic neu-
ropathy staging.
15 No significant age, sex, or height difference 
was found among the groups (MyD1: n=12, age range 17-54 
years, mean age 35.8 years; DM: n=12, age range 31-56 years, 
mean age 38.8 years; control group: n=25, age range 26-54 
years, mean age 37.0 years).
Multiple excitability measurements
The multiple excitability measurements are listed in Table 2. 
The CMAP amplitude was significantly lower in the MyD1 
group than in the DM and normal control groups (MyD1, 
5.4±0.9 mV; DM, 9.4±0.7 mV; normal control, 9.7±0.6 mV; 
p=0.0002). All of the other NCS parameters were normal in 
all of the groups. The rheobase tended to be higher in the MyD1 
group, but the difference did not reach statistical significance. 
The mean SDTC of the MyD1 and DM groups was within the 
range of the normal controls.
The TEd (10-20 ms), TEh (10-20 ms), and TEh (90-100 ms) 
were significantly lower in the MyD1 group than in the con-
trol group. When compared with the DM group, the patients 
with MyD1 had a significantly lower TEh (10-20 ms) and TEh Axonal Excitability of Myotonic Dystrophy 
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(90-100 ms) and exhibited a tendency toward a lower TEd 
(10-20 ms). A tendency toward a difference among groups in 
TEd (90-100 ms) was also observed, but the difference did not 
reach statistical significance (p=0.05). These results gave the 
MyD1 group a “fanned-in” TE appearance compared with the 
control and DM groups (Fig. 1A).
The refractoriness of the axonal excitability RC was signifi-
cantly greater in the MyD1 group (at 2.5 ms) than in the con-
trol group, and the MyD1 relative refractory period tended to 
be longer. In addition, the MyD1 group exhibited significantly 
greater refractoriness at 2.5 ms and subnormality compared 
with the DM group (Fig. 1B). The CTR comparison revealed 
that threshold changes in response to the 50% depolarizing 
current were similar in the MyD1 and control groups; howev-
er, threshold changes to the 100% hyperpolarizing current 
were significantly smaller for the MyD1 group than for the con-
trol group.
No significant differences were found between the DM and 
control groups with regard to the excitability indices, with the 
exception of supernormality (p=0.04). Furthermore, no signifi-
Table 1. Characteristics of the patients with myotonic dystrophy type I
No. case  Age (y)  Sex 
Duration 
of disease (m)
No. CTG 
triplet repeats 
APB power 
(MRC grade) 
Clinical 
myotonia 
Electrophysiological 
myotonia 
01  32  M  84  250  IV  +  + 
02*  37  F  -  -  V  -  + 
03  54  M  24  725  V  +  + 
04  42  M  36  1,233  V  +  + 
05  39  F  15  442  IV  +  + 
06  21  F  18  651  V  +  + 
07  49  M  36  1,775  V  +  + 
08  28  F  10  412  IV  +  + 
09  17  M  24  339  IV  +  + 
10
† 45  M  -  -  V  -  + 
11  32  M  -  1,645  III  +  + 
12  34  M  60  1,025  IV  +  + 
*Symptomatic sister of case 1, whose clinical and electromyographic features were compatible with myotonia. A genetic study was 
not conducted for her diagnosis, 
†Symptomatic mother of case 9, whose clinical and electromyographic features were compatible 
with myotonia. A genetic study was not conducted for her diagnosis.
APB: abductor pollicis brevis, MRC: medical research council, y: year, m: month.
Table 2. Indices of multiple excitability according to group
MyD1 (n=12) DM (n=12) Control (n=25) p value*  p  value
†
Strength-duration 
Strength–duration time constant (ms)  0.44 (0.04)  0.42 (0.03)  0.43 (0.02)  NS  NS 
Rheobase (mA)  4.8 (0.6)0 3.2 (0.3)0 3.2 (0.2)0  NS  NS 
Threshold electronus (%) 
TEd (10–20 ms)  66.3 (1.0)0 70.7 (1.9)0 72.6 (1.0)0 0.04  NS 
TEd (90–100 ms)  44.1 (1.5)0 45.7 (1.6)0 48.7 (0.7)0 NS (0.05)  NS 
TEh (10–20 ms)  -71.9 (3.1)0 -82.3 (1.9)0 -80.7 (1.2)0 0.007  0.03 
TEh (90–100 ms)  -116.7 (7.3)0 -135.8 (5.8)0 -139.3 (4.0)0 0.02  0.04 
Recovery cycle 
Refractoriness (2.5 ms) (%)  71.0 (21.7)  24.7 (3.7)0 27.8 (6.3)0 0.009  0.009 
Relative refractory period (ms)  3.59 (0.19)  3.13 (0.11)  3.04 (0.06)  NS (0.05)  NS 
Supernormality (%)  -21.1 (3.4)0 -21.7 (1.7)0 -27.9 (1.5)0 NS  NS 
Late subnormality (%)  17.7 (7.2)0 12.7 (1.0)0 15.6 (0.6)0 NS  0.02 
Current–threshold relationship 
50% depolarizing current in CTR (%)  50.4 (1.7)0 53.0 (1.0)0 56.9 (0.9)0 NS  NS 
100% hyperpolarizing current in CTR (%)  -319.1 (34.2)  -.358.9 (30.6)  -360.2 (12.3)  0.01  NS 
Data are expressed as mean (SEM) values. 
*MyD1 versus control group, 
†MyD1 versus DM group; no significant changes were found between the DM and control groups, with 
the exception of supernormality (p=0.04).
DM: diabetes mellitus, TEd: depolarizing threshold electrotonus, TEh: hyperpolarizing threshold electrotonus, CTR: current-threshold re-
lationship.Bae JS et al.
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cant correlation was found between the length of the CTG 
expansion and any multiple excitability parameters in the pa-
tients with MyD1.
In summary, the MyD1 group exhibited abnormalities in ax-
onal excitability parameters including the “fanned-in” pheno-
menon in TE and increased refractoriness and relative refrac-
tory period duration. Although not all of the differences be-
tween the MyD1 and DM groups reached statistical signific-
ance, many of the excitability properties exhibited a tendency 
toward significance. Furthermore, with the exception of super-
normality, the DM and control groups exhibited a similar pat-
tern of excitability properties.
Discussion
Our results demonstrate that the change in peripheral axonal 
excitability is more pronounced in patients who have MyD1 but 
not DM than in those who have DM with no PN and than in 
healthy controls. The MyD1 group exhibited a “fanned-in” ph-
enomenon in TE, and an increased refractoriness and relative 
refractory period duration. The change in excitability proper-
ties did not differ significantly between the DM and control 
groups. However, the absolute values of excitability indices and 
the mean response curve suggested that the DM group was at 
an intermediate state between the MyD1 and control groups. 
Moreover, the data from the MyD1 and DM groups exhibited 
a tendency toward statistical significance for several the ex-
citability properties.
The nerve excitability properties in patients with MyD1 were 
previously evaluated by Krishnan et al.
16 Our results for pa-
tients with MyD1 compared with healthy controls are similar 
to those of Krishnan et al. except that our patients exhibited a 
tendency toward an increased rheobase. Thus, our study con-
firmed a characteristic pattern of peripheral nerve abnormali-
Fig. 1. The mean excitability response in the myotonic dystrophy type 
I (MyD1), diabetes mellitus (DM), and control groups. The graph shows 
the threshold electrotonus (A), recovery cycle (B), and current-thresh-
old relationship (C) according to group. The response pattern of the 
MyD1 group differs from that of the other groups, whereas the pattern 
is similar in the control and DM groups. The statistical data are given 
in Table 2.
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ty in MyD1: depolarized axonal membrane potential, impair-
ed nodal voltage-gated transient Na
+ channel function, and an 
increase in the axon excitation threshold, although these results 
did not reach statistical significance.
Controversy exists regarding the etiology of PN in MyD1. PN 
is reported to be present in 20-30% of patients with MyD1.
17-20 
It has been suggested that PN is an axonal neuropathy in MyD1 
that tends to progress in a stepwise fashion, irrespective of the 
clinical severity of the myopathy.
19 Although age, disease durat-
ion, and the clinical severity of the MyD1 are considered to be 
associative factors for the presence of PN in MyD1,
9,10 clinicians 
do not agree on the underlying cause of PN. Furthermore, con-
troversy continues over whether PN is a primary effect of MyD1 
or a secondary complication of DM or drug side effects.
6,10 DM 
commonly causes PN and is itself a frequent endocrinological 
complication of MyD1; thus, diabetic PN could be secondary 
manifestation.
Conventional NCS is commonly used to diagnose PN, de-
spite problems with diagnostic sensitivity, the lack of pathophy-
siological information, and the possibility that it may result in 
a false-negative diagnosis, particularly in the early stages when 
changes to the nerve are minimal.
11,12 Thus, NCS may not de-
tect mild or early PN and may indicate a normal result when 
subclinical PN is present in patients with either MyD1 or DM.
The recently developed NET, which uses the threshold-tr-
acking technique, can provide insight into the ionic mechanisms 
underlying the pathophysiology of axonal dysfunction in PN 
and motor neuron disease. This technique assesses nerve excit-
ability properties and can analyze clinical features and positive 
neuromuscular symptoms that are not detected by conventio-
nal NCS.
21 Moreover, the technique can measure discrete ch-
anges in peripheral nerve axon excitability and has been used 
to identify a distinct pattern of altered excitability properties 
in diabetic PN.
22-24
Krishnan et al.
16 demonstrated abnormal peripheral nerve 
excitability in patients with MyD1; the findings of the present 
study confirm their results. The etiology of this abnormal peri-
pheral nerve activity is not known. Krishnan et al. noted that 
despite a clinical assessment showing no DM or glucose in-
tolerance in their patients, it was possible that some had a sub-
clinical alteration in glucose metabolism. Our study, which 
was designed to identify the mechanism underlying PN in 
MyD1, compared patients with MyD1 and early PN, and those 
with DM and no PN. Our finding of a significant difference in 
peripheral nerve activity in the MyD1 compared with the DM 
and normal control groups suggests that PN is a primary ef-
fect of MyD1 rather than a secondary complication of DM.
The present study had some limitations. It performed a 
cross-sectional comparison between the electrophysiological 
data produced by automated NET and NCS; we did not evalu-
ate pathological findings or autonomic nerve function, parti-
cularly in the DM group. As such, our conclusions stem from 
a neurophysiological perspective rather than from functional 
evidence. It is known that small-fiber sensory or autonomic fi-
bers are the initial target of pathological changes in DM. How-
ever, like conventional NCS, NET reflects only large, myeli-
nated, fast-conducting fibers. Furthermore, the number of pa-
tients in the study was small, which may have limited the sta-
tistical power of our analyses; however, patients who have 
early MyD1 and uncomplicated DM with a normal NCS are 
scarce. Future work should involve a more precise evaluation 
of the overall status of the disease and larger patient numbers.
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